Literature DB >> 9843909

Inhibition of adenosine-1 receptor-mediated preglomerular vasoconstriction in AT1A receptor-deficient mice.

T Traynor1, T Yang, Y G Huang, L Arend, M I Oliverio, T Coffman, J P Briggs, J Schnermann.   

Abstract

The effect of the adenosine type 1 receptor agonist N6-cyclohexyladenosine (CHA) on glomerular vascular reactivity was studied in male angiotensin II type 1A (AT1A) receptor knockout mice (9). Vascular reactivity was assessed as the response of stop-flow pressure (PSF) to infusion of CHA into loops of Henle using micropuncture techniques. In AT1A +/+ mice at ambient arterial blood pressure (96.7 +/- 2.8 mmHg), the presence of CHA (10 (-5) M) in the perfusate increased PSF responses from 6.8 +/- 0.6 to 14.3 +/- 0.9 mmHg when the loop of Henle of the index nephron was perfused and from 0.7 +/- 0.3 to 12.3 +/- 1.0 mmHg when the loop of an adjacent nephron was perfused. At reduced arterial blood pressure (82.8 +/- 1. 3 mmHg), index nephron perfusion with CHA increased PSF responses from 4.5 +/- 0.3 to 9.4 +/- 0.4 mmHg. In AT1A -/- mice with a mean arterial blood pressure of 80 +/- 1.9 mmHg, CHA increased PSF responses only from 0.1 +/- 0.3 to 3.6 +/- 0.54 mmHg during index nephron perfusion and from 0.25 +/- 0.2 to 2.7 +/- 0.55 mmHg during adjacent nephron perfusion, significantly less than in wild-type animals (P < 0.001). Responses to CHA were intermediate in AT1A +/- mice. Thus AT1A receptor knockout mice show a markedly reduced constrictor response to CHA both in the presence and absence of simultaneous activation of the tubuloglomerular feedback system. These data support the notion of a functional interaction between adenosine and angiotensin II in the regulation of afferent arteriolar tone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843909     DOI: 10.1152/ajprenal.1998.275.6.F922

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  ATP, P2 receptors and the renal microcirculation.

Authors:  Edward W Inscho
Journal:  Purinergic Signal       Date:  2009-03-18       Impact factor: 3.765

Review 3.  Adenosine receptors and the kidney.

Authors:  Volker Vallon; Hartmut Osswald
Journal:  Handb Exp Pharmacol       Date:  2009

Review 4.  Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice.

Authors:  Jurgen Schnermann; Josephine P Briggs
Journal:  Kidney Int       Date:  2008-04-16       Impact factor: 10.612

Review 5.  0.9% saline is neither normal nor physiological.

Authors:  Heng Li; Shi-ren Sun; John Q Yap; Jiang-hua Chen; Qi Qian
Journal:  J Zhejiang Univ Sci B       Date:  2016-03       Impact factor: 3.066

6.  Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors.

Authors:  D Sun; L C Samuelson; T Yang; Y Huang; A Paliege; T Saunders; J Briggs; J Schnermann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Adenosine Receptors Influence Hypertension in Dahl Salt-Sensitive Rats: Dependence on Receptor Subtype, Salt Diet, and Sex.

Authors:  Edwin K Jackson; Delbert G Gillespie; Zaichuan Mi; Dongmei Cheng
Journal:  Hypertension       Date:  2018-06-25       Impact factor: 10.190

8.  Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior.

Authors:  Edward W Inscho; Anthony K Cook; John D Imig; Catherine Vial; Richard J Evans
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures.

Authors:  Ilan Goldenberg; Asher Shainberg; Kenneth A Jacobson; Vladimir Shneyvays; Ehud Grossman
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 10.  P2 receptors in renal autoregulation.

Authors:  Zhengrong Guan; Robert C Fellner; Justin Van Beusecum; Edward W Inscho
Journal:  Curr Vasc Pharmacol       Date:  2014       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.